According to the literature, CXCR3+CD8+ T cells have been identified as a biomarker that is associated with survival in melanoma patients with stage III disease (28), suggesting a potential role of this marker in SARS-CoV-2–infected patient survival. The gene discussed is CD8A; the disease is melanoma.